MISC

国際誌
2013年11月

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.

Cancer chemotherapy and pharmacology
  • Mitsugu Kochi
  • Yuji Akiyama
  • Tatsuya Aoki
  • Ken Hagiwara
  • Takao Takahashi
  • Katsuji Hironaka
  • Futoshi Teranishi
  • Fumihiko Osuka
  • Masahiro Takeuchi
  • Masashi Fujii
  • Toshifusa Nakajima
  • 全て表示

72
5
開始ページ
1097
終了ページ
102
記述言語
英語
掲載種別
Scientific Journal
DOI
10.1007/s00280-013-2292-9

PURPOSE: The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer. METHODS: Patients with metastatic colorectal cancer were eligible for enrollment. On day 1 of a 14-day cycle, patients received bevacizumab 5 mg/kg, irinotecan 150 mg/m², and L-leucovorin 200 mg/m² as an intravenous infusion, followed by 5-FU 400 mg/m² as an intravenous bolus and then 5-FU 2,400 mg/m² as an 46-h intravenous infusion. This treatment cycle was repeated. The primary endpoint was progression-free survival (PFS). RESULTS: We enrolled 40 patients, but one withdrew consent before starting treatment. The remaining 39 patients received a total of 509 cycles of FOLFIRI plus bevacizumab (median 11 per patient; range 1-30). The median PFS was 11.5 months, the median overall survival (OS) was 22.0 months, and the 1-year OS rate was 81.8 %. All 39 patients had adverse events. Grade 3 or 4 neutropenia and stomatitis occurred in 21 (53.9 %) and 4 (10.3 %) patients, respectively. CONCLUSION: Our results suggest that FOLFIRI plus bevacizumab is a clinically effective regimen with a manageable toxicity profile as first-line chemotherapy in patients with metastatic colorectal cancer.

リンク情報
DOI
https://doi.org/10.1007/s00280-013-2292-9
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/24057041
URL
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84887139796&origin=inward
ID情報
  • DOI : 10.1007/s00280-013-2292-9
  • ISSN : 0344-5704
  • PubMed ID : 24057041

エクスポート
BibTeX RIS